Tagged with R

Protek In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly after the world financial crisis, which hit Russia particularly hard. Why did you choose this very risky period for the…

PAREXEL Russia PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better than its competitors? For pharma companies, time is always money—the tendency and drive, therefore, is to get products to market…

NAARI AG Russia/CIS Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you believe the game has changed for foreign companies looking to play in Russia? Firstly, it is necessary to specify the…

Scottish Enterprise What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish government has set out an economic strategy in which they identify six key industrial sectors for the growth of the…

Merz Russia You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may view this as a step down. What attracted you to this organization? First of all, the position itself was very…

Biocodex Russia You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history of working in the luxury goods industry, but no pharmaceutical management experience. How do you navigate the challenge of entering…

Lupin Russia Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to drug registration and establishing the mutual recognition of clinical trials. On a socio-economic level, wow would you describe the synergies…

BOIRON Romania Records show that the field of homeopathy has a long history in Romania, dating back to the late 1800s. However, the real growth only really took off in the 1990s. Can you give a brief introduction on homeopathy in Romania and what have been some of the key milestones for…

Biopharmaceutical investments of RVC (RVC BioFund) Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have necessitated the creation of Biofund? Biofund was created on January 24th, 2011. There are two stakeholders in the creation of…

Serbia Serbia has had an undoubtedly troubled history since the breakup of Yugoslavia in the early 1990s. A costly war and ensuing UN sanctions have left the country’s economy a few years behind those of its regional counterparts. The subsequent global financial crisis in the late 2000s resulted in another hit…

Petrovax Pharm Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of this organization, as the Pharma 2020 initiatives set clear industry targets in terms of a greater proliferation of locally-made, innovative…

Bayer UK/Ireland Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave mature markets, such as the UK and how do you aim to position the company locally? The UK is perceived…